French Guidelines on Patients With Cancer and SARS-CoV-2 Infection
As reported by You et al in The Lancet Oncology, a representative group of French medical and radiation oncologists formulated...
ASCO Coronavirus Resources
As the coronavirus (COVID-19) continues to spread, organizations all over the world are focusing on the health and safety of their...
Imaging-Based Radiotherapy Target Volume Reduction in Locally Advanced NSCLC
In a European trial (PET-Plan) reported in The Lancet Oncology, Nestle et al found that the use of reduced radiotherapy target volumes...
Does Pembrolizumab Show Activity in Some Rare Cancers?
A study published by Naing et al in the Journal for ImmunoTherapy of Cancer found that treatment with pembrolizumab demonstrated...
Polypharmacy and Inpatient Hospitalization Rates in Older Patients With Cancer
In a study published by Grace Lu-Yao, PhD, and colleagues in the Journal of Geriatric Oncology, researchers found hospitalization rates...
Sponsored Content
Sponsored By AstraZeneca
PARP Inhibitors: Changing the Treatment Paradigm in Ovarian Cancer
Association of Germline Variant Status and Response to Neoadjuvant Chemotherapy in High-Risk Early Breast Cancer
In a study of the GeparOcto trial population reported in JAMA Oncology, Pohl-Rescigno et al found that presence of germline BRCA1/2 variants was associated with increased rates of complete pathologic response (pCR) to neoadjuvant chemotherapy in women with high-risk early breast cancer, and that a...
Impact of Genes on Total Number and Type of Nevi
A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer. “The goal was to investigate the genetic underpinnings of different mole classes, or...
Pemigatinib for Previously Treated Advanced Cholangiocarcinoma
In the phase II FIGHT-202 study reported in The Lancet Oncology, Ghassan K. Abou-Alfa, MD, and colleagues found that the fibroblast growth factor receptor 1 (FGFR1), FGFR2, and FGFR3 inhibitor pemigatinib was active in patients with previously treated locally advanced or metastatic...
Bispecific Antibodies: Successes and Challenges
Bispecific T-cell engager (BiTE) antibodies, such blinatumomab, may be the most appealing type of bispecific antibodies, a class of manufactured constructs that is expected to expand into the solid tumor space, according to Hermann Einsele, MD, Professor of Medicine at the University of Würzburg,...
Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma
In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...
Bendamustine/Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis
In a phase II trial reported in the Journal of Clinical Oncology, Suzanne Lentzsch, MD, PhD, and colleagues found that the combination of bendamustine and dexamethasone showed activity in patients with relapsed/refractory systemic light-chain amyloidosis. As stated by the investigators, there...
Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...
Toni K. Choueiri, MD, on an HIF2A Inhibitor for Advanced Clear Cell RCC
Jacob J. Adashek, DO, on Immunoregulatory Molecules, Cancer Genes, and Therapeutic Insights
Sara M. Tolaney, MD, MPH, on HER2-Positive Breast Cancer: ATEMPT Trial on T-DM1 vs Paclitaxel Plus Trastuzumab
Francis P. Worden, MD, on the Role of Induction Chemotherapy in Laryngeal Preservation
